Similar Items: Lecanemab and amyloid‐related imaging abnormalities: Real‐world data from a single center experience
- Six‐month real‐world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than in dementia
- From clinical trial to clinical experience: Lecanemab therapy in a real‐world case series
- Real‐world use of lecanemab: patient pathway findings from a US multicenter study
- Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial
- Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging
- Simulation of long‐term lecanemab treatment effect on Alzheimer's disease progression